Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses current treatments in acute myeloid leukemia (AML) and what advancements in AML therapies are on the horizon. Venetoclax, a BCL-2 inhibitor, is a major player in the current treatment options, proving highly effective in combination with azacitidine, and acting synergistically with numerous other treatments. Evidence of its combined activity with gilteritinib was presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. Immunotherapy will likely be a future focus in AML with promising early results from magrolimab trials, the first immunotherapy in AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.